In theory, CCL2 blockade can simultaneously inhibit the recruitment of immunosuppressive cells and enhance the infiltration of killer T cells to achieve tumor suppression, but the clinical benefit of targeting the CCL2/CCR2 axis is still pending. Here, CCL2 is linked to neoplasm.